美股异动 | 生物医药股SNTI飙升近400%，其白血病药物临床试验效果良好
本周一（12月2日），生物医药股 Senti Biosciences, Inc. 飙升近400%，截至发稿报10.9美元：
消息面上，公司周一宣布，在其针对复发或难治性血液恶性肿瘤（即白血病）的Senti-202研究性细胞疗法的I期试验中，三名接受治疗的急性髓系白血病患者中有两名实现了完全缓解。
Senti Biosciences表示，这两名患者均接受了最低剂量的治疗，治疗后未检测到任何可测量的残留病灶，并分别维持了超过四个月和三个月的缓解状态。
该疗法耐受性良好，未报告出现剂量限制性毒性，Senti Biosciences补充道。目前，剂量递增阶段的患者入组工作正在进行中，预计将于2025年公布更多数据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10